Key result
Transapical aortic valve implantation with the Edwards bioprosthesis achieved a 96.7% procedural success rate, with actuarial survival rates of 73.8%, 67.2%, and 41.0% at 1, 2, and 4 years.
Why the study?
What are the 4-year outcomes of transapical TAVI with the Edwards bioprosthesis in high-risk patients unsuitable for conventional surgery or transfemoral access?
Population
61 patients not suitable for conventional surgery or transfemoral implantation, mean age 81.0 ± 6.8 years…
Design
Cohort
Follow-up
4 years
Authors
Loading...
May support transapical TAVI in select high-risk patients; leaves open need for randomized comparisons.
Cohort (n=61)
No
What are the 4-year outcomes of transapical TAVI with the Edwards bioprosthesis in high-risk patients unsuitable for conventional surgery or transfemoral access?
Transapical TAVI with the Edwards bioprosthesis provides satisfactory long-term outcomes in high-risk patients unsuitable for conventional surgery or transfemoral access.
Litzler et al. (2012) conducted a cohort in Aortic valve disease unsuitable for conventional surgery or transfemoral implantation (n=61). Transapical transcatheter aortic valve implantation (TAVI) with Edwards bioprosthesis was evaluated on Successful valve implantation. Transapical aortic valve implantation with the Edwards bioprosthesis achieved a 96.7% procedural success rate, with actuarial survival rates of 73.8%, 67.2%, and 41.0% at 1, 2, and 4 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: